{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T10:41:47.442983+00:00","company":{"ticker":"LNAI","cik":1527728,"company_name":"Lunai Bioworks Inc."},"pagination":{"limit":100,"returned":79,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Paseco ApS","detail":"other","count":3,"first_seen":"2023-02-23T23:59:59+00:00","last_seen":"2023-02-23T23:59:59+00:00","evidence_fact_ids":[177149,177150,177151]},{"display_name":"GEDi Cube Intl Ltd.","detail":"equity_purchase","count":2,"first_seen":"2023-09-29T23:59:59+00:00","last_seen":"2024-02-14T23:59:59+00:00","evidence_fact_ids":[74931,110058]},{"display_name":"Clemann Group, SAS","detail":"asset_purchase","count":1,"first_seen":"2026-03-30T23:59:59+00:00","last_seen":"2026-03-30T23:59:59+00:00","evidence_fact_ids":[26750]},{"display_name":"Dawson James Securities, Inc.","detail":"atm_program","count":1,"first_seen":"2025-12-03T23:59:59+00:00","last_seen":"2025-12-03T23:59:59+00:00","evidence_fact_ids":[143319]},{"display_name":"Lincoln Park Capital Fund, LLC","detail":"equity_purchase","count":1,"first_seen":"2023-06-27T23:59:59+00:00","last_seen":"2023-06-27T23:59:59+00:00","evidence_fact_ids":[135106]},{"display_name":"Weird Science LLC","detail":"license","count":1,"first_seen":"2024-03-07T23:59:59+00:00","last_seen":"2024-03-07T23:59:59+00:00","evidence_fact_ids":[69027]},{"display_name":"three of the Company’s holders of secured promissory notes","detail":"equity_purchase","count":1,"first_seen":"2026-03-30T23:59:59+00:00","last_seen":"2026-03-30T23:59:59+00:00","evidence_fact_ids":[26749]}],"ma_counterparty":[{"display_name":"GEDi Cube Intl Ltd.","detail":"acquisition","count":1,"first_seen":"2024-02-14T23:59:59+00:00","last_seen":"2024-02-14T23:59:59+00:00","evidence_fact_ids":[74935]},{"display_name":"Neurobridge IP Holdings Incorporated","detail":"acquisition","count":1,"first_seen":"2026-05-01T23:59:59+00:00","last_seen":"2026-05-01T23:59:59+00:00","evidence_fact_ids":[23477]}]},"facts":[{"fact_type":"exchange_compliance_notice","fact_key":"7472accb381886f27460e77d5bb7323fcf2400e5","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-11T21:30:26+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-04-28","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(2)","reported_value":null,"rule_numbers":["5550(b)(2)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(b)(2)).","evidence_excerpt":"April 28, 2026 of an\nadditional staff determination letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC regarding compliance with Nasdaq\nListing Rule 5550(b)(2). The soliciting material and related disclosures included in the Original Report under the captions “The\nSpecial Meeting and the Proposals Being Voted On,” “Additional Information and Where to Find It” and “Participants\nin the Solicitation,” are no longer applicable because the Special Meeting has been held and the proposals submitted to a vote of\nstockholders thereat have been acted upon. Except as expressly se","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000705","anchor_url":"https://secwatch.observer/filing/0001731122-26-000705#claim-7472accb381886f27460e77d5bb7323fcf2400e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000705/0001731122-26-000705-index.htm"},{"fact_type":"equity_issuance","fact_key":"c2b388994f979eee6e81c16de724aabbf9812411","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"action":"rights_modification","consideration_text":"$20,000,000","effective_date":"2026-05-01","item_codes_triggered":["3.03"],"purchaser":null,"security_type":"preferred_stock","shares_text":null},"claim":"Lunai Bioworks Inc. issued preferred stock for $20,000,000.","evidence_excerpt":"of the Company, the holders of the Series B Preferred Stock are entitled to a senior liquidation preference equal to the\naggregate Stated Value of the Series B Preferred Stock ($20,000,000), and to the extent that, upon receipt of the Stockholder Approval,\nthe Series B Preferred Stock will become convertible into shares of common stock at a fixed Conversion Price","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000653","anchor_url":"https://secwatch.observer/filing/0001731122-26-000653#claim-c2b388994f979eee6e81c16de724aabbf9812411","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm"},{"fact_type":"ma_transaction","fact_key":"7a51f34b6207f458258129b5d4c42de89ad98343","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2026-05-01","consideration_text":"$20,000,000 aggregate stated value of Series B Convertible Preferred Stock","counterparty":"Neurobridge IP Holdings Incorporated","effective_date":"2026-05-01","item_codes_triggered":["2.01"]},"claim":"Lunai Bioworks Inc. completed an acquisition involving Neurobridge IP Holdings Incorporated for $20,000,000 aggregate stated value of Series B Convertible Preferred Stock (closed 2026-05-01).","evidence_excerpt":"nto an Agreement and Plan of Merger (the “Merger Agreement”) with Neurobridge IP Holdings Incorporated, a Delaware corporation\n(“Holdings”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000653","anchor_url":"https://secwatch.observer/filing/0001731122-26-000653#claim-7a51f34b6207f458258129b5d4c42de89ad98343","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm"},{"fact_type":"material_agreement","fact_key":"e6cdf9866aaad8efccb1216b5ca8523696f0862c","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":null,"effective_date":"2026-05-01","item_codes_triggered":["1.01"],"value_text":null},"claim":"Lunai Bioworks Inc. entered into Merger Agreement (effective 2026-05-01).","evidence_excerpt":"The foregoing description of the Merger Agreement is a summary only and\nis qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000653","anchor_url":"https://secwatch.observer/filing/0001731122-26-000653#claim-e6cdf9866aaad8efccb1216b5ca8523696f0862c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"6e7a3c22a7eda8e2ed57963799f210558dddf4fb","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-06-01","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00","notice_date":"2026-04-20","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"April 20, 2026, the Company received notice from\nthe Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement\nunder Nasdaq Listing Rule 5550(b)(1)\n (the “S","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000653","anchor_url":"https://secwatch.observer/filing/0001731122-26-000653#claim-6e7a3c22a7eda8e2ed57963799f210558dddf4fb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d6c4359ecb2a24a812b6e2ce4bc7887dc248fd12","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-01T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2027-06-01","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$2.5 million","notice_date":"2026-04-20","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 20, 2026, the Company received notice from\nthe Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement\nunder Nasdaq Listing Rule 5550(b)(1)\n (the “S","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000653","anchor_url":"https://secwatch.observer/filing/0001731122-26-000653#claim-d6c4359ecb2a24a812b6e2ce4bc7887dc248fd12","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm"},{"fact_type":"equity_issuance","fact_key":"31e721d5f5b67e36b4a8e4d8f91804f775f9f2e7","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"part of the debt exchange","effective_date":"2026-03-24","item_codes_triggered":["3.02"],"purchaser":"three of the Company's holders of secured promissory notes","security_type":"warrant","shares_text":"an aggregate of 1,433,621 additional shares of common stock"},"claim":"Lunai Bioworks Inc. issued an aggregate of 1,433,621 additional shares of common stock of warrant to three of the Company's holders of secured promissory notes for part of the debt exchange.","evidence_excerpt":"common stock purchase warrants to acquire an aggregate of 1,433,621 additional shares of common stock (the “Warrants”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000502","anchor_url":"https://secwatch.observer/filing/0001731122-26-000502#claim-31e721d5f5b67e36b4a8e4d8f91804f775f9f2e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm"},{"fact_type":"equity_issuance","fact_key":"6ac64e9a0e0a30fd8b42b5b6cb5bfa35ee982ec1","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"cancellation and extinguishment of an aggregate of $828,770.14 of outstanding principal and accrued interest","effective_date":"2026-03-24","item_codes_triggered":["3.02"],"purchaser":"three of the Company's holders of secured promissory notes","security_type":"common_stock","shares_text":"an aggregate of 3,909,293 shares"},"claim":"Lunai Bioworks Inc. issued an aggregate of 3,909,293 shares of common stock to three of the Company's holders of secured promissory notes for cancellation and extinguishment of an aggregate of $828,770.14 of outstanding principal and accrued interest.","evidence_excerpt":"Pursuant to the Debt Exchange Agreements, the Holders agreed to cancel and extinguish an aggregate of $828,770.14 of outstanding principal and accrued interest owed under the Investor Notes in exchange for an aggregate of 3,909,293 shares of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000502","anchor_url":"https://secwatch.observer/filing/0001731122-26-000502#claim-6ac64e9a0e0a30fd8b42b5b6cb5bfa35ee982ec1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm"},{"fact_type":"material_agreement","fact_key":"bf4dd7b3413ce5b0f64e1f312e537d8c921b1377","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Acquisition Agreement","agreement_type":"asset_purchase","counterparty":"Clemann Group, SAS","effective_date":"2026-03-26","item_codes_triggered":["1.01"],"value_text":"$20.0 million"},"claim":"Lunai Bioworks Inc. entered into Acquisition Agreement with Clemann Group, SAS valued at $20.0 million (effective 2026-03-26).","evidence_excerpt":"On March 26, 2026, the Company entered into a binding agreement (the “Acquisition Agreement”) with Clemann Group, SAS, or its assignee (the “Seller”), pursuant to which the Company agreed to acquire certain blood-brain barrier delivery technology and central nervous system Alzheimer’s drug assets (the “Transaction”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000502","anchor_url":"https://secwatch.observer/filing/0001731122-26-000502#claim-bf4dd7b3413ce5b0f64e1f312e537d8c921b1377","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm"},{"fact_type":"material_agreement","fact_key":"5136c380c6a527e30872c8ff55c983bf723b4a71","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Debt Exchange Agreements","agreement_type":"equity_purchase","counterparty":"three of the Company’s holders of secured promissory notes","effective_date":"2026-03-24","item_codes_triggered":["1.01"],"value_text":"$828,770.14"},"claim":"Lunai Bioworks Inc. entered into Debt Exchange Agreements with three of the Company’s holders of secured promissory notes valued at $828,770.14 (effective 2026-03-24).","evidence_excerpt":"On March 24, 2026, Lunai Bioworks, Inc. (the “Company”) entered into separate debt exchange agreements (collectively, the “Debt Exchange Agreements”) with three of the Company’s holders (each a “Holder”) of secured promissory notes (the “Investor Notes”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000502","anchor_url":"https://secwatch.observer/filing/0001731122-26-000502#claim-5136c380c6a527e30872c8ff55c983bf723b4a71","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c0af2abb43594ab8a5b1b073180c34105f7c8b49","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-02-23T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":"2026-03-26","immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-02-06","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding other.","evidence_excerpt":"February 6, 2026, Lunai Bioworks Inc. (the “Company”)\nreceived a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that the Staff had determined to delist the Company’s securities from Nasdaq. As previously disclosed, the Company timely requested a hearing before\nthe Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On February 17, 2026, the Company received written notice from Nasdaq that\nthe Panel has granted the Company’s request for a hearing. The hearing has been scheduled for March 26, 2026. A","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000282","anchor_url":"https://secwatch.observer/filing/0001731122-26-000282#claim-c0af2abb43594ab8a5b1b073180c34105f7c8b49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000282/0001731122-26-000282-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"82aebf21bee25232335edd5823cd539e3ce59786","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"company_response":"requested hearing before Nasdaq Hearings Panel","compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-02-06","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2) and Nasdaq Listing Rule 5810(c)(3)(A)(iv)","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)(iv)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).","evidence_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-26-000221","anchor_url":"https://secwatch.observer/filing/0001731122-26-000221#claim-82aebf21bee25232335edd5823cd539e3ce59786","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm"},{"fact_type":"material_agreement","fact_key":"995c365d707f5affda2108ae72c27dd22b039c22","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-12-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"At-the-Market Sales Agreement","agreement_type":"atm_program","counterparty":"Dawson James Securities, Inc.","effective_date":"2025-12-02","item_codes_triggered":["1.01"],"value_text":"up to $11.70 million"},"claim":"Lunai Bioworks Inc. entered into At-the-Market Sales Agreement with Dawson James Securities, Inc. valued at up to $11.70 million (effective 2025-12-02).","evidence_excerpt":"On December 2, 2025, Lunai Bioworks, Inc. (the “Company”) entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent”), pursuant to which the Company may offer and sell (the “Offering”) shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $11.70 million, from time to time through the Sales Agent as the Company’s sales agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001625","anchor_url":"https://secwatch.observer/filing/0001731122-25-001625#claim-995c365d707f5affda2108ae72c27dd22b039c22","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001625/0001731122-25-001625-index.htm"},{"fact_type":"equity_issuance","fact_key":"ffd6a97992d0d60013ff5fa5547bdce55621fa89","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-11-25T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"included in aggregate gross proceeds of $3,133,333","effective_date":"2025-11-24","item_codes_triggered":["3.02"],"purchaser":"an accredited investor","security_type":"warrant","shares_text":"1,044,444 three-year warrants, executable after sixty (60) days"},"claim":"Lunai Bioworks Inc. issued 1,044,444 three-year warrants, executable after sixty (60) days of warrant to an accredited investor for included in aggregate gross proceeds of $3,133,333.","evidence_excerpt":"and 1,044,444 three-year warrants, executable after sixty (60) days (the “Warrants”) for aggregate gross proceeds of $3,133,333","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001597","anchor_url":"https://secwatch.observer/filing/0001731122-25-001597#claim-ffd6a97992d0d60013ff5fa5547bdce55621fa89","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001597/0001731122-25-001597-index.htm"},{"fact_type":"equity_issuance","fact_key":"2965755da856e88948bb99212576a862cfeb3e1e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-11-25T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$1.00 per share","effective_date":"2025-11-24","item_codes_triggered":["3.02"],"purchaser":"an accredited investor","security_type":"common_stock","shares_text":"3,133,333 shares of its common stock"},"claim":"Lunai Bioworks Inc. issued 3,133,333 shares of its common stock of common stock to an accredited investor for $1.00 per share.","evidence_excerpt":"On November 24, 2025, Lunai Bioworks Inc. (“Lunai” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company agreed to sell, and the Investor agreed to purchase, in a private placement, 3,133,333 shares of its common stock, par value $0.001 per share (the “Shares”), at a purchase price of $1.00 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001597","anchor_url":"https://secwatch.observer/filing/0001731122-25-001597#claim-2965755da856e88948bb99212576a862cfeb3e1e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001597/0001731122-25-001597-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"52a9f0c80a52efa4d8d5465c20d1d6a6bd796029","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-11-06T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"shareholders","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-11-06","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5620(a)","reported_value":null,"rule_numbers":["5620(a)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5620(a)).","evidence_excerpt":"otifying the Company that it was no longer in compliance with Nasdaq Listing Rule 5620(a), which requires that listed companies hold\nan annual meeting of shareholders no later than one year after the end of their fiscal year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001495","anchor_url":"https://secwatch.observer/filing/0001731122-25-001495#claim-52a9f0c80a52efa4d8d5465c20d1d6a6bd796029","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001495/0001731122-25-001495-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"7fa5312ab31ce8571c8de8e3a786f0fd57f67219","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-10-30T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-10-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(2) for Capital Market","reported_value":null,"rule_numbers":["5550(b)(2)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"October 27, 2025, Lunai Bioworks (the “Company”)\nreceived a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nindicating that the Company is not in compliance with the $35 million minimum Market Value of Listed Securities (“MVLS”)\nrequirement set forth in Nasdaq Listing Rule 5550(b)(2) for Capital Market. The Notice stated that the Company’s MVLS had\nbeen below $35 million for the previous 30 consecutive business days, and that, in accordance with Nasdaq rules, the Company has a period\nof 180 calendar days, or until April 27","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001731122-25-001446","anchor_url":"https://secwatch.observer/filing/0001731122-25-001446#claim-7fa5312ab31ce8571c8de8e3a786f0fd57f67219","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001446/0001731122-25-001446-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d437eb7b63f0d09c5da5bbc81a712cdb4dc7e86e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-10-16T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-10-15","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"13(a) of the Exchang e Act. ☐ Item 3.01 Notice of Delisting\nor Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October\n15, 2025, Lunai Bioworks (the “Company”) received a Notice from the NASDAQ Stock Market that the Company has regained compliance\nwith Listing Rule 5550(a)(2). On April 14, 2025, the NASDAQ staff notified the Company that its common stock failed to maintain\na minimum bid price of $1.00 over the previous thirty (30) consecutive business days as required by the Listing Rules of the NASDAQ Stock\nMarket. Since then, the staff of NASDAQ has determin","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001399","anchor_url":"https://secwatch.observer/filing/0001731122-25-001399#claim-d437eb7b63f0d09c5da5bbc81a712cdb4dc7e86e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001399/0001731122-25-001399-index.htm"},{"fact_type":"governance_change","fact_key":"fb82bf513e5d4d2c930afecec52c38d177709673","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-09-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-09-29","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock, par value unchanged, effective September 29, 2025; authorized shares unchanged at 350,000,000."},"claim":"Lunai Bioworks Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock, par value unchanged, effective September 29, 2025; authorized shares unchanged at 350,000,000 (effective 2025-09-29).","evidence_excerpt":"On September 18, 2025, Lunai Bioworks, Inc. (the “ Company ”) filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “ Certificate of Amendment ”) with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September 29, 2025 (the “ Reverse Stock Split ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001297","anchor_url":"https://secwatch.observer/filing/0001731122-25-001297#claim-fb82bf513e5d4d2c930afecec52c38d177709673","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001297/0001731122-25-001297-index.htm"},{"fact_type":"restructuring_charge","fact_key":"ae8f3829a38defb6f5113918a01e779a5e244fa1","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-09-05T23:59:59+00:00","payload":{"affected_area":null,"charge_text":null,"effective_date":"2025-09-02","event_type":"impairment","headcount_text":null,"item_codes_triggered":["2.06"]},"claim":"Lunai Bioworks Inc. announced a impairment.","evidence_excerpt":"management determined on September 2, 2025 that a material impairment of assets has occurred. The Company expects to record an impairment charge for the quarter ending September 30, 2025, however, is unable to make a good faith estimate of the same or the cash expenditures resulting from the impairment charge, if any, at the time of this filing.","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0001731122-25-001204","anchor_url":"https://secwatch.observer/filing/0001731122-25-001204#claim-ae8f3829a38defb6f5113918a01e779a5e244fa1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001204/0001731122-25-001204-index.htm"},{"fact_type":"governance_change","fact_key":"4a26a283e60d6ec989db8393382f0a5c4f90ae32","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-08-26T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-08-20","item_codes_triggered":["5.03"],"summary_text":"Changed corporate name from Renovaro Inc. to Lunai Bioworks Inc."},"claim":"Lunai Bioworks Inc.: Changed corporate name from Renovaro Inc. to Lunai Bioworks Inc (effective 2025-08-20).","evidence_excerpt":"On August 18, 2025, Renovaro Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to change its corporate name from ”Renovaro Inc.” to ”Lunai Bioworks Inc.” (the “Name Change”). The Name Change became effective on August 20, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001173","anchor_url":"https://secwatch.observer/filing/0001731122-25-001173#claim-4a26a283e60d6ec989db8393382f0a5c4f90ae32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001173/0001731122-25-001173-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"90c4320ed7648e2a67918d565814a44c8f068e75","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-08-06T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-10-31","deficiency_type":"shareholders","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-07-07","notice_type":"deficiency_notice","plan_due_date":"2025-10-31","raw_rule_text":null,"reported_value":null,"rule_numbers":["5620(a)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).","evidence_excerpt":"July 7, 2025, Renovaro Inc. (the “Company”) received a notice\nfrom The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a),\nwhich requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. On August 5, 2025, the Company received written confirmation from Nasdaq\nthat it has accepted the Company’s plan to regain compliance and has granted an extension until October 31, 2025, for the Company\nto hold its annual meeting of shareholders. The Company intends to hold the ann","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-001076","anchor_url":"https://secwatch.observer/filing/0001731122-25-001076#claim-90c4320ed7648e2a67918d565814a44c8f068e75","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001076/0001731122-25-001076-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"2033413a20410610b420d4f8baee14ea7802103e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-07-14T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"shareholders","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-07-07","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5620(a)","5810(c)(2)(G)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).","evidence_excerpt":"July 7, 2025, Renovaro Inc. (the “Company”) received a written\nnotice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying\nthe Company that it is no longer in compliance with Nasdaq Listing Rule 5620(a), which requires that listed companies hold an annual meeting\nof shareholders no later than one year after the end of their fiscal year. The Company did not hold its annual meeting of shareholders within twelve\nmonths of the end of its fiscal year ended June 30, 2024, and therefore did not satisfy this requirement. Pursuant to Nasdaq Listi","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-25-000971","anchor_url":"https://secwatch.observer/filing/0001731122-25-000971#claim-2033413a20410610b420d4f8baee14ea7802103e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000971/0001731122-25-000971-index.htm"},{"fact_type":"executive_change","fact_key":"de3bb129ed","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-06-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-05-30","interim":false,"role":"Chief Executive Officer of GEDi Cube B.V.","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Maurice van Tilburg resigned as Chief Executive Officer of GEDi Cube B.V. at Lunai Bioworks Inc..","evidence_excerpt":"On May 30, 2025, Maurice van Tilburg notified Renovaro Inc. (the “Company”) of his intent to resign from the office of Chief Executive Officer of GEDi Cube B.V., a wholly-owned indirect subsidiary of the Company, which resignation was effective May 30, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-25-000829","anchor_url":"https://secwatch.observer/filing/0001731122-25-000829#claim-de3bb129ed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000829/0001731122-25-000829-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"1a2c7f1c9af72dc92039ad3dbbf48e18f6e25703","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-04-18T23:59:59+00:00","payload":{"company_response":"The Company intends to monitor the closing bid price of its Common Stock and is considering its options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.","compliance_status":"deficient","cure_deadline":"2025-10-13","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-04-14","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"April 14, 2025, Renovaro Inc.\n(the “ Company ”) received a deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) informing the\nCompany that its common stock, par value $0.0001 per share (the “ Common Stock ”), fails to comply with the $1 minimum\nbid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid\nprice of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate\neffect on the listing of the Common Stock on The Nasdaq Capital Market an","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-25-000592","anchor_url":"https://secwatch.observer/filing/0001731122-25-000592#claim-1a2c7f1c9af72dc92039ad3dbbf48e18f6e25703","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000592/0001731122-25-000592-index.htm"},{"fact_type":"executive_change","fact_key":"7818596748","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-01-13T23:59:59+00:00","payload":{"action":"removed","action_category":"departure","departure_tone":"termination","effective_date":"2025-01-06","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":"Nathen Fuentes","successor_named":true},"claim":"Simon Tarsh was removed as Interim Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"In connection with Mr. Fuentes’ appointment as Chief Financial Officer, Simon Tarsh was removed as Interim Chief Financial Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-25-000067","anchor_url":"https://secwatch.observer/filing/0001731122-25-000067#claim-7818596748","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm"},{"fact_type":"executive_change","fact_key":"a1b35e7f52","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-01-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-06","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nathen Fuentes was appointed as Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"Effective January 6, 2025, the board of directors (the “ Board ”) of Renovaro Inc. (the “ Company ” or “ Renovaro ”) appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-25-000067","anchor_url":"https://secwatch.observer/filing/0001731122-25-000067#claim-a1b35e7f52","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm"},{"fact_type":"executive_change","fact_key":"1d1d78d419","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2025-01-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-12-30","interim":false,"role":"Chief Executive Officer of GEDi Cube B.V.","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Maurice van Tilburg was appointed as Chief Executive Officer of GEDi Cube B.V. at Lunai Bioworks Inc..","evidence_excerpt":"On December 30, 2024, the Board appointed Maurice van Tilburg, age 53, as Chief Executive Officer of GEDi Cube B.V.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-25-000017","anchor_url":"https://secwatch.observer/filing/0001731122-25-000017#claim-1d1d78d419","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000017/0001731122-25-000017-index.htm"},{"fact_type":"executive_change","fact_key":"901d7e3053","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-11-21T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-22","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Francois Binette PhD resigned as Chief Operating Officer at Lunai Bioworks Inc..","evidence_excerpt":"On November 15, 2024, Francois Binette PhD, Renovaro Inc.’s Chief Operating Officer, tendered his resignation as Chief Operating Officer, effective November 22, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001842","anchor_url":"https://secwatch.observer/filing/0001731122-24-001842#claim-901d7e3053","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001842/0001731122-24-001842-index.htm"},{"fact_type":"executive_change","fact_key":"bfd56e8480","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mark Collins was appointed as Director at Lunai Bioworks Inc..","evidence_excerpt":"Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-bfd56e8480","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"3599b8411c","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Douglas Calder was appointed as Director at Lunai Bioworks Inc..","evidence_excerpt":"Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-3599b8411c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"501395f4dc","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James McNulty was appointed as Director at Lunai Bioworks Inc..","evidence_excerpt":"Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-501395f4dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"ef633d688b","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Maurice van Tilburg was appointed as Director at Lunai Bioworks Inc..","evidence_excerpt":"Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-ef633d688b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"0fadd41c54","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Weinstein was appointed as Director at Lunai Bioworks Inc..","evidence_excerpt":"Once Messrs. Weinstein, van Tilburg, McNulty, Calder and Collins’ Board committee membership is determined","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-0fadd41c54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"01e0454920","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-15","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Rene Sindlev resigned as Chairman of the Board at Lunai Bioworks Inc..","evidence_excerpt":"On October 15, 2024, Rene Sindlev resigned as the Chairman of the Board of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-01e0454920","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"addc6d4ff4","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2024-10-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Carol Brosgart resigned as Director at Lunai Bioworks Inc..","evidence_excerpt":"On October 13, 2024, Gregg Alton the Lead Independent Director on the Board, Jayne McNicol and Carol Brosgart formally advised the Board of the Company that they were resigning from the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-addc6d4ff4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"e8d0bcb378","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2024-10-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jayne McNicol resigned as Director at Lunai Bioworks Inc..","evidence_excerpt":"On October 13, 2024, Gregg Alton the Lead Independent Director on the Board, Jayne McNicol and Carol Brosgart formally advised the Board of the Company that they were resigning from the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-e8d0bcb378","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"112bb62aa0","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2024-10-13","interim":false,"role":"Lead Independent Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Gregg Alton resigned as Lead Independent Director at Lunai Bioworks Inc..","evidence_excerpt":"On October 13, 2024, Gregg Alton the Lead Independent Director on the Board, Jayne McNicol and Carol Brosgart formally advised the Board of the Company that they were resigning from the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-112bb62aa0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"38f6ca9f33","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2024-10-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James Sapirstein resigned as Director at Lunai Bioworks Inc..","evidence_excerpt":"On October 12, 2024, James Sapirstein a member of the Board formally advised the Board of the Company that he was resigning from the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-38f6ca9f33","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"7090d8923e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Karen Brink resigned as Director at Lunai Bioworks Inc..","evidence_excerpt":"On October 12, 2024, Karen Brink resigned as a director on the Board of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-7090d8923e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"e4d2f099bd","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ruud Hendriks resigned as Director at Lunai Bioworks Inc..","evidence_excerpt":"On the same date, Ruud Hendriks resigned as a director on the Board of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-e4d2f099bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"00c71350d1","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Avram Miller resigned as Director at Lunai Bioworks Inc..","evidence_excerpt":"On October 11, 2024, Avram Miller resigned as a director on the Board of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001606","anchor_url":"https://secwatch.observer/filing/0001731122-24-001606#claim-00c71350d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001606/0001731122-24-001606-index.htm"},{"fact_type":"executive_change","fact_key":"b504fae4b3","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-07-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-27","interim":false,"role":"Director and Chair of Special Litigation Committee","role_category":"director","successor_name":null,"successor_named":false},"claim":"Leni Boeren resigned as Director and Chair of Special Litigation Committee at Lunai Bioworks Inc..","evidence_excerpt":"On June 27, 2024, Leni Boeren provided notice of her resignation as a member of the Board of Directors of Renovaro Inc. (the “ Company ”), with such resignation being effective June 27, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-001085","anchor_url":"https://secwatch.observer/filing/0001731122-24-001085#claim-b504fae4b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001085/0001731122-24-001085-index.htm"},{"fact_type":"executive_change","fact_key":"223b4ee847","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-03-13T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Simon Tarsh","successor_named":true},"claim":"Ms. Puche departed as Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"Ms. Puche, the Company’s outgoing Chief Financial Officer, said: “After more than 5 years at the Company, I am ready for a new phase in my life.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000419","anchor_url":"https://secwatch.observer/filing/0001731122-24-000419#claim-223b4ee847","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/0001731122-24-000419-index.htm"},{"fact_type":"executive_change","fact_key":"38f6fe43bb","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-03-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-11","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Simon Tarsh was appointed as Interim Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"The board of directors (the “Board”) of Renovaro Inc. (the “Company”) appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company, effective March 11, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-000419","anchor_url":"https://secwatch.observer/filing/0001731122-24-000419#claim-38f6fe43bb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/0001731122-24-000419-index.htm"},{"fact_type":"material_agreement","fact_key":"655a285d5dce29efba3a600e48d0a77c7d4dca7e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"action":"termination","agreement_name":"License Agreement","agreement_type":"license","counterparty":"Weird Science LLC","effective_date":"2024-03-01","item_codes_triggered":["1.02"],"value_text":null},"claim":"Lunai Bioworks Inc. terminated License Agreement with Weird Science LLC (effective 2024-03-01).","evidence_excerpt":"On March 1, 2024, Renovaro Inc. (the “Company”) received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly-owned subsidiary of the Company, dated February 16, 2018 (the “License Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000372","anchor_url":"https://secwatch.observer/filing/0001731122-24-000372#claim-655a285d5dce29efba3a600e48d0a77c7d4dca7e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000372/0001731122-24-000372-index.htm"},{"fact_type":"executive_change","fact_key":"a0f1c43ef0","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-03-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-21","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Luisa Puche resigned as Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"Luisa Puche tendered her resignation as Chief Financial Officer of Renovaro Inc. (the “Company”), effective as of March 21, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-000345","anchor_url":"https://secwatch.observer/filing/0001731122-24-000345#claim-a0f1c43ef0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000345/0001731122-24-000345-index.htm"},{"fact_type":"governance_change","fact_key":"8862c5de24806a68a1a14932d36bd27e83f71151","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-13","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to change corporate name from Renovaro Biosciences Inc. to Renovaro Inc."},"claim":"Lunai Bioworks Inc.: Amended certificate of incorporation to change corporate name from Renovaro Biosciences Inc. to Renovaro Inc (effective 2024-02-13).","evidence_excerpt":"In connection with the closing of the Transaction, on February 13, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of Certificate of Incorporation (the “Name Change Amendment”) to change its corporate name from “Renovaro Biosciences Inc.” to “Renovaro Inc.”, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000246","anchor_url":"https://secwatch.observer/filing/0001731122-24-000246#claim-8862c5de24806a68a1a14932d36bd27e83f71151","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/0001731122-24-000246-index.htm"},{"fact_type":"ma_transaction","fact_key":"e57f3ee2f35efeb738c22c69a4b91ac50cf1e14e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-02-13","consideration_text":"70,834,183 shares of common stock plus Earnout Shares","counterparty":"GEDi Cube Intl Ltd.","effective_date":"2024-02-13","item_codes_triggered":["2.01"]},"claim":"Lunai Bioworks Inc. completed an acquisition involving GEDi Cube Intl Ltd. for 70,834,183 shares of common stock plus Earnout Shares (closed 2024-02-13).","evidence_excerpt":"collectively, the “GEDi\nCube Shares”) in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller’s pro\nrata percentage of an aggregate of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (“Common\nStock”), which represents the 67,224,089 shares of Common Stock issued and outstanding as of the","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001731122-24-000246","anchor_url":"https://secwatch.observer/filing/0001731122-24-000246#claim-e57f3ee2f35efeb738c22c69a4b91ac50cf1e14e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/0001731122-24-000246-index.htm"},{"fact_type":"material_agreement","fact_key":"b7d13dd0bbd1ccdf96c52cff5fa98c4fb2e31e80","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Second Amendment to Stock Purchase Agreement","agreement_type":"equity_purchase","counterparty":"GEDi Cube Intl Ltd.","effective_date":"2024-02-09","item_codes_triggered":["1.01"],"value_text":"Amendment to Stock Purchase Agreement to increase number of directors from nine to ten and adjust in"},"claim":"Lunai Bioworks Inc. amended Second Amendment to Stock Purchase Agreement with GEDi Cube Intl Ltd. valued at Amendment to Stock Purchase Agreement to increase number of directors from nine to ten and adjust in (effective 2024-02-09).","evidence_excerpt":"On February 9, 2024, the parties to the Stock Purchase Agreement entered into a Second Amendment to Stock Purchase Agreement (the “Amendment”), pursuant to which the parties amended the Stock Purchase Agreement to increase (i) the number of directors comprising the Company’s Board of Directors (the “Board”) effective upon the Closing from nine to ten individuals; (ii) the number of directors to be designated by the Company to serve on the Board effective as of the Closing from four to five individuals; and (iii) the number of such directors designated by the Company who are required to qualify as an “independent director” under Listing Rule 5605(a) of the Nasdaq Stock Market from three to four individuals.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000246","anchor_url":"https://secwatch.observer/filing/0001731122-24-000246#claim-b7d13dd0bbd1ccdf96c52cff5fa98c4fb2e31e80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/0001731122-24-000246-index.htm"},{"fact_type":"executive_change","fact_key":"9adb6bcc1d","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Karen Brink was appointed as Director at Lunai Bioworks Inc..","evidence_excerpt":"On February 11, 2024, the Board appointed Karen Brink, the Chief Growth Officer of GEDi Cube, to the Board, effective upon the closing of the Transaction, to fill the vacancy created by Mr. Grønfeldt-Sørensen’s resignation.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-000246","anchor_url":"https://secwatch.observer/filing/0001731122-24-000246#claim-9adb6bcc1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/0001731122-24-000246-index.htm"},{"fact_type":"executive_change","fact_key":"98d8f2004c","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":"Karen Brink","successor_named":true},"claim":"Henrik Grønfeldt-Sørensen resigned as Director at Lunai Bioworks Inc..","evidence_excerpt":"On February 11, 2024, Henrik Grønfeldt-Sørensen notified the Board of his decision to resign as a director of the Company, effective as of the closing of the Transaction.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-24-000246","anchor_url":"https://secwatch.observer/filing/0001731122-24-000246#claim-98d8f2004c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/0001731122-24-000246-index.htm"},{"fact_type":"governance_change","fact_key":"c9c35fdf66af0444da6106134fdad5446c004070","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-02-07T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-01","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares from 110,000,000 to 360,000,000 and common stock from 100,000,000 to 350,000,000"},"claim":"Lunai Bioworks Inc.: Increased authorized shares from 110,000,000 to 360,000,000 and common stock from 100,000,000 to 350,000,000 (effective 2024-02-01).","evidence_excerpt":"On February 1, 2024, Renovaro Biosciences Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Authorized Share Amendment”) to the Company’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of capital stock of the Company from 110,000,000 to 360,000,000 and to increase the total number of authorized shares of common stock, par value $0.0001 per share, of the Company from 100,000,000 to 350,000,000, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000207","anchor_url":"https://secwatch.observer/filing/0001731122-24-000207#claim-c9c35fdf66af0444da6106134fdad5446c004070","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000207/0001731122-24-000207-index.htm"},{"fact_type":"shareholder_vote","fact_key":"dea234ba85c379d2405e13786ae02ceb749eaeae","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-01-25T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-25","outcome":"passed","proposal_text":"Approval to adjourn meeting if necessary for proxy solicitation","proposal_type":"other","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"2,006","votes_against":"780,020","votes_for":"32,805,974","votes_withheld":null}]},"claim":"Lunai Bioworks Inc. shareholders approved Approval to adjourn meeting if necessary for proxy solicitation at the 2024-01-25 meeting.","evidence_excerpt":"Proposal No. 5 : Approval to adjourn the Meeting, if necessary, for the purpose of soliciting additional proxies to approve any one or more of the foregoing proposals to be considered at the Meeting","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000159","anchor_url":"https://secwatch.observer/filing/0001731122-24-000159#claim-dea234ba85c379d2405e13786ae02ceb749eaeae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000159/0001731122-24-000159-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d9c4777485ff2521074d6fd8777b5fc5c0af35eb","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-01-25T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-25","outcome":"passed","proposal_text":"Amendment to 2023 Plan to increase shares available for awards by 5,000,000","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,394,478","subject":null,"votes_abstain":"2,601","votes_against":"45,717","votes_for":"32,145,204","votes_withheld":null}]},"claim":"Lunai Bioworks Inc. shareholders approved Amendment to 2023 Plan to increase shares available for awards by 5,000,000 at the 2024-01-25 meeting.","evidence_excerpt":"Proposal No. 4 : Approval of an amendment to the 2023 Plan to increase the number of shares of Common Stock available for awards under the 2023 Plan by five million (5,000,000) shares . The stockholders approved this proposal as follows: Votes For 32,145,204 Votes Against 45,717 Abstentions 2,601 Broker Non-Votes 1,394,478","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000159","anchor_url":"https://secwatch.observer/filing/0001731122-24-000159#claim-d9c4777485ff2521074d6fd8777b5fc5c0af35eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000159/0001731122-24-000159-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ec3894bbf8a5a299b77d9f2472393b259f568b2b","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-01-25T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-25","outcome":"passed","proposal_text":"Decrease in exercise price of outstanding stock options under the 2019 and 2023 Equity Incentive Plans","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,394,478","subject":null,"votes_abstain":"2,114","votes_against":"1,025,166","votes_for":"31,166,242","votes_withheld":null}]},"claim":"Lunai Bioworks Inc. shareholders approved Decrease in exercise price of outstanding stock options under the 2019 and 2023 Equity Incentive Plans at the 2024-01-25 meeting.","evidence_excerpt":"Proposal No. 3 : Approval of a decrease in the exercise price of the outstanding stock options held by Renovaro’s employees and consultants granted pursuant to the Enochian BioSciences Inc. 2019 Equity Incentive Plan","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000159","anchor_url":"https://secwatch.observer/filing/0001731122-24-000159#claim-ec3894bbf8a5a299b77d9f2472393b259f568b2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000159/0001731122-24-000159-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9ee3cec026ac6a0f771d95456fb89af9c86a7fd8","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-01-25T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-25","outcome":"passed","proposal_text":"Amendment to increase authorized shares of capital stock","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"2,910","votes_against":"96,582","votes_for":"33,488,508","votes_withheld":null}]},"claim":"Lunai Bioworks Inc. shareholders approved Amendment to increase authorized shares of capital stock at the 2024-01-25 meeting.","evidence_excerpt":"Proposal No. 2 : Approval of an amendment to Renovaro’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of capital stock of Renovaro from one hundred ten million (110,000,000) to three hundred sixty million (360,000,000)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000159","anchor_url":"https://secwatch.observer/filing/0001731122-24-000159#claim-9ee3cec026ac6a0f771d95456fb89af9c86a7fd8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000159/0001731122-24-000159-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6f4d657ec1222ef4450adf24f157789232074ed4","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2024-01-25T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-25","outcome":"passed","proposal_text":"Approval of issuance of shares of Common Stock pursuant to the Stock Purchase Agreement","proposal_type":"merger_approval","results":[{"broker_non_votes":"1,394,478","subject":null,"votes_abstain":"1,997","votes_against":"10,324","votes_for":"32,181,201","votes_withheld":null}]},"claim":"Lunai Bioworks Inc. shareholders approved Approval of issuance of shares of Common Stock pursuant to the Stock Purchase Agreement at the 2024-01-25 meeting.","evidence_excerpt":"Proposal No. 1 : Approval, for purposes of Listing Rule 5635 of The Nasdaq Stock Market LLC (“Nasdasq”), of the issuance of shares of Common Stock , pursuant to the Stock Purchase Agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-24-000159","anchor_url":"https://secwatch.observer/filing/0001731122-24-000159#claim-6f4d657ec1222ef4450adf24f157789232074ed4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000159/0001731122-24-000159-index.htm"},{"fact_type":"executive_change","fact_key":"2d45d8cffd","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-10-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-11","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Avram Miller was appointed as director at Lunai Bioworks Inc..","evidence_excerpt":"appointed Avram Miller to the Board, effective October 11, 2023, to fill a vacancy.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-23-001860","anchor_url":"https://secwatch.observer/filing/0001731122-23-001860#claim-2d45d8cffd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001860/0001731122-23-001860-index.htm"},{"fact_type":"executive_change","fact_key":"feb627a39e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-10-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-04","interim":false,"role":"Independent Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ruud Hendriks was appointed as Independent Director at Lunai Bioworks Inc..","evidence_excerpt":"increased the size of the Board to ten members and appointed Leni Boeren and Ruud Hendriks to the Board effective immediately, to fill vacancies created.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-23-001825","anchor_url":"https://secwatch.observer/filing/0001731122-23-001825#claim-feb627a39e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001825/0001731122-23-001825-index.htm"},{"fact_type":"executive_change","fact_key":"3e45ee9ad2","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-10-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-04","interim":false,"role":"Independent Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Leni Boeren was appointed as Independent Director at Lunai Bioworks Inc..","evidence_excerpt":"increased the size of the Board to ten members and appointed Leni Boeren and Ruud Hendriks to the Board effective immediately, to fill vacancies created.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-23-001825","anchor_url":"https://secwatch.observer/filing/0001731122-23-001825#claim-3e45ee9ad2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001825/0001731122-23-001825-index.htm"},{"fact_type":"debt_financing","fact_key":"1650d73e82ee7bfbc633903617fb2bfadee51907","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-10-10T23:59:59+00:00","payload":{"counterparty":"five investors","effective_date":"2023-10-05","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"12% per annum","item_codes_triggered":["2.03"],"maturity_text":"September 5, 2024","principal_text":"$2,105,264"},"claim":"Lunai Bioworks Inc. incurred convertible notes of $2,105,264 with five investors at 12% per annum maturing September 5, 2024.","evidence_excerpt":"Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible\nPromissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264. The Company received a total of $2,000,000\nin gross proceeds from the offering, taking into account the 5% original issue discount. The Notes bear an interest rate of 12%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-001841","anchor_url":"https://secwatch.observer/filing/0001731122-23-001841#claim-1650d73e82ee7bfbc633903617fb2bfadee51907","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm"},{"fact_type":"material_agreement","fact_key":"d064e30f3e3794ab25115b204006d104cdad5bac","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-10-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Subscription Agreements","agreement_type":"notes_offering","counterparty":"five investors","effective_date":"2023-09-05","item_codes_triggered":["1.01"],"value_text":"aggregate principal amount of $2,105,264"},"claim":"Lunai Bioworks Inc. entered into Subscription Agreements with five investors valued at aggregate principal amount of $2,105,264 (effective 2023-09-05).","evidence_excerpt":"Between September 5, 2023 and October 5, 2023, Renovaro Biosciences Inc. (the “Company”) entered into Subscription Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001731122-23-001841","anchor_url":"https://secwatch.observer/filing/0001731122-23-001841#claim-d064e30f3e3794ab25115b204006d104cdad5bac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm"},{"fact_type":"material_agreement","fact_key":"aa9671980569fa3d49cf56dc68623a3b39a3d48a","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-09-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"merger","counterparty":"GEDi Cube Intl Ltd.","effective_date":"2023-09-28","item_codes_triggered":["1.01"],"value_text":null},"claim":"Lunai Bioworks Inc. entered into Purchase Agreement with GEDi Cube Intl Ltd. (effective 2023-09-28).","evidence_excerpt":"On September 28, 2023, Renovaro Biosciences Inc. (NASDAQ: RENB) (“ Renovaro ”), entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with GEDi Cube Intl Ltd.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-001762","anchor_url":"https://secwatch.observer/filing/0001731122-23-001762#claim-aa9671980569fa3d49cf56dc68623a3b39a3d48a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001762/0001731122-23-001762-index.htm"},{"fact_type":"governance_change","fact_key":"6c99014541aea747ef85ce549c739b425c73c02a","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-08-07T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-08-01","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designation for Series A Convertible Preferred Stock establishing rights and preferences"},"claim":"Lunai Bioworks Inc.: Filed Certificate of Designation for Series A Convertible Preferred Stock establishing rights and preferences (effective 2023-08-01).","evidence_excerpt":"On August 1, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Certificate of Designation ”) establishing the series of Preferred Stock designated as the Series A Convertible Preferred Stock with the rights and preferences discussed below.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-001396","anchor_url":"https://secwatch.observer/filing/0001731122-23-001396#claim-6c99014541aea747ef85ce549c739b425c73c02a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/0001731122-23-001396-index.htm"},{"fact_type":"governance_change","fact_key":"eb89b79d917409d43abcd71d3f7961d4730aa211","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-08-07T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-08-01","item_codes_triggered":["5.03"],"summary_text":"Changed corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc."},"claim":"Lunai Bioworks Inc.: Changed corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc (effective 2023-08-01).","evidence_excerpt":"On August 1, 2023, at 5:04 P.M. Eastern Time, Enochian Biosciences Inc. filed with the Secretary of the State of the State of Delaware a Certificate of Amendment of Certificate of Incorporation to change its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc., effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-001389","anchor_url":"https://secwatch.observer/filing/0001731122-23-001389#claim-eb89b79d917409d43abcd71d3f7961d4730aa211","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001389/0001731122-23-001389-index.htm"},{"fact_type":"shareholder_vote","fact_key":"263067757ec7f0fde921ce8ba9bab627bebf4c79","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-21","outcome":"passed","proposal_text":"Ratification of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"13,456","votes_against":"16,107","votes_for":"20,327,508","votes_withheld":null}]},"claim":"Lunai Bioworks Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-07-21 meeting.","evidence_excerpt":"Proposal No. 3 : Ratification of Independent Registered Public Accounting Firm . The stockholders ratified Sadler, Gibb & Associates, LLC as the Company's independent registered public accounting firm as follows: Votes For 20,327,508 Votes Against 16,107 Abstentions 13,456","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-23-001319","anchor_url":"https://secwatch.observer/filing/0001731122-23-001319#claim-263067757ec7f0fde921ce8ba9bab627bebf4c79","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001319/0001731122-23-001319-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3215c4eafd60b475978cd3915e084c31df8da819","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-21","outcome":"passed","proposal_text":"Approval of 2023 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,528,369","subject":null,"votes_abstain":"8,269","votes_against":"34,914","votes_for":"18,785,519","votes_withheld":null}]},"claim":"Lunai Bioworks Inc. shareholders approved Approval of 2023 Equity Incentive Plan at the 2023-07-21 meeting.","evidence_excerpt":"Proposal No. 2 : Approval of 2023 Equity Incentive Plan . The stockholders approved the 2023 Equity Incentive Plan as follows: Votes For 18,785,519 Votes Against 34,914 Abstentions 8,269 Broker Non-Votes 1,528,369","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-23-001319","anchor_url":"https://secwatch.observer/filing/0001731122-23-001319#claim-3215c4eafd60b475978cd3915e084c31df8da819","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001319/0001731122-23-001319-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5b8ceee38c9f38dbd1ebfdd35cf0075b0800787e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-07-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-21","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,528,369","subject":"Renè Sindlev","votes_abstain":null,"votes_against":null,"votes_for":"18,661,936","votes_withheld":"166,766"},{"broker_non_votes":"1,528,369","subject":"Dr. Mark R. Dybul","votes_abstain":null,"votes_against":null,"votes_for":"18,662,825","votes_withheld":"165,877"},{"broker_non_votes":"1,528,369","subject":"Dr. Carol L. Brosgart","votes_abstain":null,"votes_against":null,"votes_for":"18,652,095","votes_withheld":"176,607"},{"broker_non_votes":"1,528,369","subject":"Gregg Alton","votes_abstain":null,"votes_against":null,"votes_for":"17,343,287","votes_withheld":"1,485,415"},{"broker_non_votes":"1,528,369","subject":"James Sapirstein","votes_abstain":null,"votes_against":null,"votes_for":"17,122,111","votes_withheld":"1,706,591"},{"broker_non_votes":"1,528,369","subject":"Henrik Gronfeldt-Sorensen","votes_abstain":null,"votes_against":null,"votes_for":"18,659,827","votes_withheld":"168,875"},{"broker_non_votes":"1,528,369","subject":"Jayne McNicol","votes_abstain":null,"votes_against":null,"votes_for":"17,247,573","votes_withheld":"1,581,129"}]},"claim":"Lunai Bioworks Inc. shareholders approved Election of Directors at the 2023-07-21 meeting.","evidence_excerpt":"Proposal No. 1 : The election of Renè Sindlev, Dr. Mark R. Dybul, Dr. Carol L. Brosgart, Gregg Alton, James Sapirstein, Henrik Gronfeldt-Sorensen and Jayne McNicol for terms until the next annual meeting of stockholders or until each such director's successor shall have been duly elected and qualified . The stockholders elected each of the seven directors by the following votes: Director Votes For Votes Withheld Broker Non-Votes Renè Sindlev 18,661,936 166,766 1,528,369 Dr. Mark R. Dybul 18,662,825 165,877 1,528,369 Dr. Carol L. Brosgart 18,652,095 176,607 1,528,369 Gregg Alton 17,343,287 1,485,415 1,528,369 James Sapirstein 17,122,111 1,706,591 1,528,369 Henrik Gronfeldt-Sorensen 18,659,827 168,875 1,528,369 Jayne McNicol 17,247,573 1,581,129 1,528,369","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-23-001319","anchor_url":"https://secwatch.observer/filing/0001731122-23-001319#claim-5b8ceee38c9f38dbd1ebfdd35cf0075b0800787e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001319/0001731122-23-001319-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"74cb4c0a7e1406c0b36c2ad73567af6aba6ca628","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-07-11T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-01-03","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00","notice_date":"2023-07-07","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2) and 5810(c)(3)(A)","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"July 7, 2023, Enochian Biosciences Inc. (the “ Company ”) received a deficiency notice from The Nasdaq Stock\nMarket (“ Nasdaq ”) informing the Company that its common stock, par value $0.0001 per share (the “ Common\nStock ”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under\nNasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior\nto the date of the notice from Nasdaq. Nasdaq’s\nnotice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-001290","anchor_url":"https://secwatch.observer/filing/0001731122-23-001290#claim-74cb4c0a7e1406c0b36c2ad73567af6aba6ca628","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001290/0001731122-23-001290-index.htm"},{"fact_type":"governance_change","fact_key":"344261b41b088aa00b9432adae81d1827da672f4","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-07-10T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-07-07","item_codes_triggered":["5.03"],"summary_text":"Amended and restated Article I, Section 7 of Bylaws to lower the quorum requirement for stockholder meetings from a majority of outstanding shares to one-third."},"claim":"Lunai Bioworks Inc.: Amended and restated Article I, Section 7 of Bylaws to lower the quorum requirement for stockholder meetings from a majority of outstanding shares to one-third (effective 2023-07-07).","evidence_excerpt":"The Amended and Restated Bylaws amends and restates Article I, Section 7 of the Company’s existing Bylaws in its entirety to lower the number of holders of the shares entitled to vote at a meeting of stockholders constituting a quorum, in person or by proxy, from a majority of the holders of the Company’s outstanding stock to one-third of the holders of the Company’s outstanding stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-001285","anchor_url":"https://secwatch.observer/filing/0001731122-23-001285#claim-344261b41b088aa00b9432adae81d1827da672f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001285/0001731122-23-001285-index.htm"},{"fact_type":"material_agreement","fact_key":"075774d6e19f923630404d9e2b325d33d56a27ba","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-06-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Lincoln Park Capital Fund, LLC","effective_date":"2023-06-20","item_codes_triggered":["1.01"],"value_text":"up to Twenty Million Dollars ($20,000,000)"},"claim":"Lunai Bioworks Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to Twenty Million Dollars ($20,000,000) (effective 2023-06-20).","evidence_excerpt":"Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-001210","anchor_url":"https://secwatch.observer/filing/0001731122-23-001210#claim-075774d6e19f923630404d9e2b325d33d56a27ba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/0001731122-23-001210-index.htm"},{"fact_type":"material_agreement","fact_key":"ffe2cf821c63483e68c9a7cbb4772dd54d70845e","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-02-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Security Agreement","agreement_type":"other","counterparty":"Paseco ApS","effective_date":"2022-12-30","item_codes_triggered":["1.01"],"value_text":null},"claim":"Lunai Bioworks Inc. entered into Security Agreement with Paseco ApS (effective 2022-12-30).","evidence_excerpt":"On February 16, 2023, the Company entered into a security agreement between the Company and the Holder, effective as of December 30, 2022 (the “ Security Agreement ”) under which the Company pledged and granted the Holder a first priority security interest in and lien upon all of the Company’s wholly-owned assets as collateral security for the prompt payment in full of the principal amounts of the February Notes and the March Note when due.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-000258","anchor_url":"https://secwatch.observer/filing/0001731122-23-000258#claim-ffe2cf821c63483e68c9a7cbb4772dd54d70845e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm"},{"fact_type":"material_agreement","fact_key":"adc0d3ccca0867eb9072a1815b96f894cfa54d89","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-02-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to the March Note","agreement_type":"other","counterparty":"Paseco ApS","effective_date":"2022-12-30","item_codes_triggered":["1.01"],"value_text":"$5,000,000"},"claim":"Lunai Bioworks Inc. amended Amendment to the March Note with Paseco ApS valued at $5,000,000 (effective 2022-12-30).","evidence_excerpt":"On February 16, 2023, the Company amended that certain promissory note dated March 30, 2020 in the principal amount of $5,000,000 between the Company and the Holder (the “ March Note ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-000258","anchor_url":"https://secwatch.observer/filing/0001731122-23-000258#claim-adc0d3ccca0867eb9072a1815b96f894cfa54d89","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm"},{"fact_type":"material_agreement","fact_key":"5c01c3ee2e99a75f17b7c90342a430341e0a5ed6","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-02-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amended and Restated February Notes","agreement_type":"other","counterparty":"Paseco ApS","effective_date":"2022-12-30","item_codes_triggered":["1.01"],"value_text":"$600,000"},"claim":"Lunai Bioworks Inc. amended Amended and Restated February Notes with Paseco ApS valued at $600,000 (effective 2022-12-30).","evidence_excerpt":"On February 16, 2023, the Company amended and restated those two certain convertible promissory notes between the Company and Paseco ApS (the “ Holder ”) dated February 6, 2020, each in the principal amount of $600,000 (the “ February Notes ”) by entering into two amended and restated secured convertible promissory notes, each with an effective date of December 30, 2022 and each in the principal amount of $600,000 (the “ Amended and Restated February Notes ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-23-000258","anchor_url":"https://secwatch.observer/filing/0001731122-23-000258#claim-5c01c3ee2e99a75f17b7c90342a430341e0a5ed6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c18daeb162308c1a40e88c8dd1c3c9a318e0c4a5","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2023-02-23T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-02-16","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"February 16, 2023, the Company\nreceived a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that because\nthe Company has not yet filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “ Form 10-Q ”),\nthe Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial\nreports with the Securities and Exchange Commission. As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission,\non October 17, 2022 and November 23, 2022, respectively, the Co","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-23-000258","anchor_url":"https://secwatch.observer/filing/0001731122-23-000258#claim-c18daeb162308c1a40e88c8dd1c3c9a318e0c4a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm"},{"fact_type":"executive_change","fact_key":"d0f618194a","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2022-12-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-11-01","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Francois Binette was appointed as Chief Operating Officer at Lunai Bioworks Inc..","evidence_excerpt":"On October 18, 2022, the Company appointed Francois Binette PhD, age 59, as Chief Operating Officer of the Company, effective November 1, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-22-002139","anchor_url":"https://secwatch.observer/filing/0001731122-22-002139#claim-d0f618194a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112222002139/0001731122-22-002139-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"51c178be3f3b8869567cf4794a7c2739bb025c4f","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2022-11-30T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-04-11","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2022-11-23","notice_type":"deficiency_notice","plan_due_date":"2022-12-16","raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"November 23, 2022, Enochian\nBiosciences Inc. (the “ Company ”) received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC\n(“ Nasdaq ”)stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended\nSeptember 30, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed\non Form 8-K filed with the Securities and Exchange Commission on October 21, 2022, on October 1","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001731122-22-002068","anchor_url":"https://secwatch.observer/filing/0001731122-22-002068#claim-51c178be3f3b8869567cf4794a7c2739bb025c4f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112222002068/0001731122-22-002068-index.htm"},{"fact_type":"executive_change","fact_key":"a4a3fa5752","cik":1527728,"ticker":"LNAI","company_name":"Lunai Bioworks Inc.","filed_at":"2022-03-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-03-25","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Carl Sandler resigned as member of the Board of Directors at Lunai Bioworks Inc..","evidence_excerpt":"On March 25, 2022, Carl Sandler provided notice of his resignation as a member of the Board of Directors of Enochian Biosciences Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001731122-22-000565","anchor_url":"https://secwatch.observer/filing/0001731122-22-000565#claim-a4a3fa5752","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112222000565/0001731122-22-000565-index.htm"}]}